- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Subjective Saturation Response in Japan
Total 19 results
-
Jewish General HospitalCompletedQuality of Life | Health, Subjective | Social InteractionCanada, Japan
-
Wakayama Medical UniversityOsaka City University; Tohoku University; Hyogo College of Medicine; Osaka City... and other collaboratorsCompleted
-
Kyoto UniversityPfizer; Astellas Pharma IncWithdrawnSepsis | CandidiasisJapan
-
TakedaTerminated
-
BayerActive, not recruitingSepsis | Disseminated Intravascular CoagulationJapan
-
AstraZenecaCompletedSeptic Shock | Severe SepsisJapan
-
Ono Pharmaceutical Co. LtdCompletedSystemic Inflammatory Response Syndrome | Acute Lung InjuryJapan
-
SymBio PharmaceuticalsRecruitingBK Virus Infection | Kidney Transplantation | NephropathyAustralia, Japan
-
Merck Sharp & Dohme LLCCompletedSkin Diseases, Infectious | Bacteremia | Soft Tissue InfectionsJapan
-
Jerry ZimmermanEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingSeptic ShockUnited States, Canada, China, Israel, Japan, Malaysia, Pakistan, Vietnam, Singapore, Saudi Arabia
-
Eisai Inc.CompletedSevere SepsisUnited States, France, Poland, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Switzerland, Argentina, Belgium, Israel, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Australia, Chile, Brazil, Austria, Italy, Czechia, Portug...
-
TakedaCompletedSepsisUnited States, United Kingdom, Belgium, Germany, Spain, Israel, Japan, Australia, Canada, Finland, Netherlands, New Zealand, Czech Republic, Puerto Rico, Austria, Sweden, Italy
-
Astellas Pharma Global Development, Inc.Approved for marketingAcute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) MutationsUnited States, Canada, Japan
-
AstraZenecaMerck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.Active, not recruitingAdvanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum ChemotherapyKorea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
-
ppharmaand GmbHBristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaboratorsActive, not recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete ResponseUnited States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
AM-PharmaTerminatedAcute Kidney Injury Due to SepsisBelgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
-
ShionogiCompletedSepsis | Bloodstream Infections (BSI) | Hospital Acquired Pneumonia (HAP) | Complicated Urinary Tract Infection (cUTI) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)United States, Brazil, Croatia, France, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United Kingdom
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain